Please assess the completion status of the following clinical trial:

Trial Title: L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Pathological confirmed melanoma 2. Advanced stage confirmed by radiological examination 3. Untreated 4. ECOG PS 0-1 6. Good organ function 7. No other severe diseases such as autoimmune disease, organ transplant, chronic infection.~8. Other tumor disease.~Exclusion Criteria:~1. Symptomatic brain metastases~2. Active infection~3. Active HBV or HCV infection~4. HIV infection~5. Autoimmune disease~6. Sensitive to drug or ingredients~7. Severe mental disorders~8. Sever disfunction of heart, liver and kidney

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- L-TIL and Tislelizumab (Type: EXPERIMENTAL): L-TIL（3-10）x10\*9/m2, Q3W, 4 cycles Tislelizumab 200mg, iv, Q3W, 1 year

Based on this trial design, predict the completion outcome and termination type (if applicable).